Carregant...
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the standard of care for patients in whom tumors are presenting...
Guardat en:
| Publicat a: | Lung Cancer (Auckl) |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2012
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5312487/ https://ncbi.nlm.nih.gov/pubmed/28210128 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S12959 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|